Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (578)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1248)
  2. Genitourinary Oncology Service (1248)
  3. Solid Tumor Oncology Division (1248)
  4. Surgery (290)
  5. Urology (281)
  6. Survivorship Research (253)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (31)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1248)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Choueiri, T. K.; Powles, T.; Escudier, B. J.; Tannir, N. M.; Mainwaring, P.; Rini, B. I.; Hammers, H. J.; Donskov, F.; Roth, B. J.; Peltola, K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study
    Meeting Abstract

    Cella, D.; Gruenwald, V.; Nathan, P. D.; Doan, J.; Dastani, H.; Taylor, F.; Bennett, B.; DeRosa, M.; Berry, S.; Broglio, K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes
    Meeting Abstract

    Carlo, M. I.; Chen, Y.; Chaim, J.; Coskey, D. T.; Woo, K.; Hsieh, J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; Lee, C. H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1b/2 study of ibrutinib combination therapy in selected advanced genitourinary and gastrointestinal tumors
    Meeting Abstract

    Berlin, J.; Posadas, E. M.; Macarulla, T. M.; Cacovean, A.; Eckert, K.; Munneke, B.; Cole, G. W.; James, D. F.; Motzer, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: The phase III JAVELIN Renal 101 trial
    Meeting Abstract

    Rini, B. I.; Choueiri, T. K.; Mariani, M.; Albiges, L.; Haanen, J. B.; Atkins, M. B.; Larkin, J.; Schmidinger, M.; Magazzù, D.; di Pietro, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Tannir, N.; Powles, T.; Motzer, R. J.; Rolland, F.; Gravis, G.; Staehler, M.; Rink, M.; Retz, M.; Csoszi, T.; McCaffrey, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
    Meeting Abstract

    Powles, T. B.; Escudier, B.; de Souza, P.; Chowdhury, S.; Pook, D.; Harmenberg, U.; Basappa, N.; Geynisman, D.; Merchan, J.; Redman, B. G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Meeting Abstract

    Ravaud, A.; Motzer, R. J.; Pandha, H. S.; Staehler, M.; George, D.; Pantuck, A. J.; Patel, A.; Chang, Y. H.; Escudier, B.; Donskov, F.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Choueiri, T.; Larkin, J.; Albiges, L.; Haanen, J. B.; Schmidinger, M.; Atkins, M. B.; Mariani, M.; Shnaidman, M.; Di Pietro, A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Evaluation of the novel "trial within a trial" design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Hessel, C.; Mangeshkar, M.; Motzer, R. J.; Escudier, B.; Powles, T. B.; Schwab, G.; Choueiri, T. K.
    Annals of Oncology (2016)

    Fulltext@MSK | Save